

InnoCare Pharma – 2020 Annual Results

March 2021

Disclaimer



These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the "Company") or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

The information or opinions contained in these materials has not been independently verified. No representation or warranty, whether expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information and opinions contained in these materials are provided as of the date of the presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. The Company, any of its affiliates, directors, supervisors, senior managers, officers, employees, advisers and their respective representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from or in reliance upon any information contained or presented in or derived from these materials or otherwise arising in connection with these materials.


These materials contain statements that reflect the Company's current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company's operations and businesses and on factors beyond the Company's control, and are subject to significant risks and uncertainties, and, accordingly, the actual results may differ materially from these forward-looking statements. You should not place undue reliance on any of such forward-looking information. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that emerge subsequent to such dates.





To Become a **Global Biopharmaceutical Leader** that Develops and Delivers **Innovative Therapies** for Patients **Worldwide**

Oncology



Autoimmune

Our Therapeutic Focus

Key Accomplishments in 2020 and Beyond



COMMERCIALIZATION

Launch of Orelabrutinib

First Commercial Product

 NMPA has granted market approval on 25 December 2020

Commercial Team and Rapid Penetration

- Over 150 experienced sales and marketing members
- First prescription on Jan 13, 2021, within 2 weeks of approval
- Rapid penetration to cover 230 cities, 870 hospitals and 4,000 doctors

BD Team Build up

 In October 2020, InnoCare appointed Dr. Manish Tandon as VP of Business Development to further strengthen the Company's BD capabilities

RESEARCH AND DEVELOPMENT

Rapid Expansion of Product Portfolio

5 Registrational Trials Ongoing

- Phase II trial for r/r WM
- Phase II trial for r/r MZL
- Phase III trial for Orelabrutinib as a first-line treatment for CLL/SLL
- Phase III trial of Orelabrutinib in combination with R-CHOP as a first-line treatment for MCL
- Phase II study for r/r MCL in the US

<u>4 Clinical Stage Assets with 15+ Trials</u> Ongoing Globally

 MS: Phase II initiated (Global trial in the U.S., Europe and China, etc.) with huge market potential

8 IND Enabling Stage Candidates

- 3 newly disclosed molecule ICP-248, ICP-488 and ICP-033
- 2 biological molecules internalized through collaboration
- 1 IND submission in 1Q2021 ICP-332
- 3-4 more to INDs to be submitted in the remainder of 2021

co 🎲

CORPORATE MILESTONES

Balanced Organization Growth

Breakthrough in Capital Market

- Raised approximately US\$393 million through a new shares placement with Hiilhouse and Vivo in Feb. 2021
- Included into HSCI with the change taking effective on 7th Sept. 2020, and included in the Stock Connect on 28th Dec. 2020
- Successful IPO in March 2020, raised approximately US\$330 million

Manufacturing Facilities

 50,000 m2 manufacturing facility complies with GMP requirements of the U.S., Europe, Japan and China, successfully obtained manufacturing license

Expansion of Talents

- In March 2021, InnoCare appointed Dr. Sean Zhang who has rich experience in clinical development as Chief Medical Officer in March 2021, who is based in U.S., demonstrating the Company's ongoing commitment to globalization
- Expanded to over 500 personnel, and the U.S. office in full-scale operations



Experienced founders and strong management team with an excellent track record

Fully integrated biopharmaceutical platform with strong in-house R&D capabilities

Worldwide rights to all product candidates

Strategically focused pipeline of potential best/first-in-class targeted therapies

- Potential best-in-class BTK inhibitor targeting B cell malignancies, has been granted market approval by the NMPA for patients with r/r MCL and r/r CLL/SLL in China in December 2020.
- · Potential best-in-class pan-FGFR and first-in-class FGFR4 inhibitor
- Second-generation pan-TRK inhibitor designed to treat patients with NTRK fusion-positive cancers
- · Potential first-in-class BTK inhibitor targeting autoimmune diseases

Culture of innovation, efficiency, and excellence: 1 commercial product, 4 clinical stage assets and multiple pre-clinical candidates to be submitted IND application in 2021

Fully-integrated Biopharma Company



Drug Discovery

All Products Developed In-house

- 100+ research scientists
- Beijing R&D center 8,300 m²
 Chemistry, biology and CMC labs



- 800 m² AAALAC-like animal facility
- Nanjing R&D center 3,350 m²
 - A state-of-the-art solid-state research lab

Novel I-O

Target

Diagnostic and biology platform

Target Identification

Protein Structure Aided Drug Design *Prof. Yigong Shi*

- Expertise in structure biology
- Deep understanding of cancer biology Novel Target Identification
- Prof. Zemin Zhang
- Single cell sequencing platform
- Big Data analysis




desian





1 commercial product 4 Clinical stage assets 8 at IND enabling stage



Commercialization

- ~150 member actively commercializing orelabrutinib since 1/13/2021
- Unrivalled medical collaboration



Clinical Development

Unparalleled Clinical Execution

- Offices in Beijing Kerry Center & Shanghai Qiantan
- ~100 Clinical development personnel
- All China trials managed in-house
- 100+ Clinical sites initiated
- 15+ trials ongoing

Manufacturing



~50,000 m² manufacturing facility in Guangzhou

- Designed to comply with both Chinese and international drug manufacturing standards
- · Consisted of 100 employees
- Completed in December 2020 and obtained manufacturing license

Top-notch Executives & Advisors





- 20+ years of experience in research and development and company management in the pharmaceutical industry
- Former CEO and CSO of BioDuro, a PPD Company
- · Former Head of Early Development Team, Cardiovascular Diseases at Merck US
- · Former Fellow at The Howard Hughes Medical Institute
- The 17th President of the Sino-American Pharmaceutical Professional Association (SAPA)

Dr. Jasmine Cui Co-founder and CEO





30+ years of experience in clinical

Hengrui Therapeutics Inc., Former

GSK. Former senior medical director

ACCP

Fellow of the American College of

Clinical Pharmacology (FCP)

development

CEO and Director



Elite Structural Biologist

中國科学院

- President and Founder of Westlake University
- Academician of the Chinese Academy of Sciences
- Foreign Associate of the National Academy of Sciences of the U.S. and European Molecular Biology Organization
- Professor of Tsinghua University and Princeton University

Prof. Yigong Shi Co-founder, President of Scientific Advisory Board

W!AS 浙江西湖高等研究院

ЕМВО

AMERICAN ACADEMY OF ARTS & SCIENCES

PRINCETON

NIVERSITY

著大学




20+ years of drug discovery experience BioDuro, Former Executive Director

of Medicinal Chemistry Pfizer, Former Principal Scientist

Albert Einstein College of Medicine, Former Postdoctoral Researcher







Former head of the bioinformatics division at Genentech Inc., USA

Prof. Zemin Zhang Scientific Advisory Board Member






CMO





Prof Arnold Levine Board Member





UBS AG, Former Healthcare Equity

Merrill Lynch Asia, Former Equity

Mehta Partners LLC, Former Equity

BANK OF AMERICA

m

Research Analyst

Research Analyst

Research Analyst

US National Academy of Sciences member

Scientific Advisory

- 20+ years of experience in product commercialization Sanofi (China), General Manager of
 - Novartis Beijing, more than 13 years

Global SVP & Greater China GM

SANOFI 🧳 🦰 Abbott 🕛 NOVARTIS







Novartis Pharmaceuticals China



BD U NOVARTIS

6





Product Pipeline - Targeting Both Proven and Novel Pathways



	Drug	Target	Indication(s)	Worldwide Rights	Pre-clinical Development	IND	Phase I	Phase II	Phase III	Launched
			r/r CLL/SLL	Ø	NDA approved: 2	5 Dec 2020				*
			r/r MCL	Ø	NDA approved: 2	5 Dec 2020				*
			r/r MZL	Ø						
			r/r WM	Ø						
			1L: CLL/SLL	Ø						
	ICP-022/ Orelabrutinib	ВТК	1L: MCL	Ø						
Liquid Tumors			r/r MCL	Ø	US Developmen	t Status				
			r/r CNSL	Ø						
			r/r non-GCB DLBC (double mutation)	L 🕜						
			Combo w/ MIL-62 (basket)	V						
	bi-specific antibody	not-disclosed	Hematology							
	ICP-248	BCL-2	Hematology	Ø	IND expected in first half of 202	22				
	ICP-490	E3 ligase	Hematology	Ø	IND expected in first half of 202	22				
Registration	al trials	Clinical Stage	Pre-clinical Stage	9						

Product Pipeline - Targeting Both Proven and Novel Pathways





Development Updates





In the U.S

Indication – Granted orphan drug status (r/r MCL)

2 Trials –

- MS: Phase II initiated (Global trial in the U.S., Europe and China, etc.)
- B-cell malignancies: Phase I basket trial completed; Initiating registrational trial in r/r MCL





Other Clinical Candidates

• ICP-192

- Early efficacy data of the Phase I/II clinical trials are promising. Of the 12 patients with FGF/FGFR gene aberrations who had completed at least one tumor assessment, the ORR was 33.3% including 1 cholangiocarcinoma patient (8.3%) achieving CR and 3 patients (25%) with PR. The DCR was 91.7% (11 of 12 patients).
- Will discuss with CDE on registrational trial plan
- □ In the U.S., we have finished first-patient dosing in advanced solid cancer patients earlier this year
- Additional pre-clinical results demonstrated ICP-192 may be efficacious for patients resistant to other FGFR therapies

ICP-723

- Dose escalation from starting dose of 1 mg to 3 mg without DLT
- The PK data showed that the plasma exposure was high, which is within the range of efficacious exposure in preclinical models. T1/2 is around 18 hours, supporting the once-daily dosing
- Dose was escalated to 3 mg in the 3rd cohort in patients with NTRK gene fusion
- ICP-105
 - In dose escalation, observed good correlation between drug exposure and PD biomarker

Growth Strategies



Imminent Launch of Orelabrutinib








- NMPA has granted market approval on 25 December
 2020
- Indication: R/R Mantle Cell Lymphoma ("MCL") and R/R Chronic Lymphocytic Leukemia/Small Cell leukemia ("CLL/SLL")
- Record setting clinical and regulatory execution:
 - From FPI to NDA filing: 1.5 years
 - From FPI to NDA approval: 2.5 years



Imminent Launch of Orelabrutinib – A strong team in place



- In a Staggered Approach Corresponding with the Timeline of entering the NRDL
- Already had ~150 sales and marketing members on board



World-class Manufacturing Facility


く INNOCARE 诺诚健华

- Successfully obtained manufacturing license for the facility
- To Meet Commercial Scale Production and Comply with GMP Requirements






Guangzhou Subsidiary



Key Financials Updates





¹Cash balance = investments measured at fair value through profit or loss + investments measured at amortised + cash and bank balance. Net cash = cash balance - convertible loan - loans and borrowings - loans from a related party



36

Key Products Highlight



Advantages and Highlights

Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies



Improved Target Selectivity Our "Point-of-Differentiation" Significant inhibition of only BTK by >90% Orelabrutinib and NO significant inhibition of other kinases Johnson & Johnson **Ibrutinib** INNOCARE abbvie BeiGene Significant inhibition of kinases other than Astra7eneca Acalabrutinib BTK Orelabrutinib Zanubrutinib Ibrutinib Acalabrutinib **Zanubrutinib** Favorable PK/PD Profile and Better Target Occupancy **Target Selectivity** The better bioavailability of Orelabrutinib tablet enables Once-daily administration at low dosage • Near 100% 24-hr BTK occupancy in blood • Safety **Improved Safety and Robust Efficacy Profile** Once-daily

Orelabrutinib is a potential best-in-class late-stage BTK inhibitor




Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont'd)



Improved Target Selectivity

KINOMEscan dendrogram



Source: "Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies" by Kaptein, A., et. al, Blood, 2018, 132 (Suppl 1) 1871; DOI: 10.1182/blood-2018-99-109973




Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont'd)



Favorable PK/PD Profile

Post-dosing plasma exposure profile



Sources: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies, Advani R.H., et al. Journal of Clinical Oncology, 2013; 31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, Byrd J.C., et al. The New England Journal of Medicine, 2016; 374(4):323-32. doi: 10.1056/NEJMoa1509981 BeiGene corporate presentation dated June 5, 2019, http://hkexir.beigene.com/media/1238/bgne-investordeck-20190605.pdf




Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont'd)



Better Target Occupancy

BTK occupancy



Abbreviations: SAD = single ascending dose; MAD = multiple ascending dose

Sources: "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia" by Byrd J.C., et al. The New England Journal of Medicine, 2016; 374(4):323-32. doi: 10.1056/NEJMoa1509981; Company filings

Orelabrutinib (ICP-022): Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont'd)



- Improved Safety and Robust Efficacy Profile ٠
- No severe AF case observed after 300+ patient dosed

Efficacy Profile

CLL/SLL

	orelabrutinib IRC (ICP-CL- 00103, N=80)	lbrutinib CLL3002 (n=106)	Acalabrutinib ASCEND (n=155)⁵	zanubrutinib IRC (BGB-3111- 205, N=91)
Median Follow- up Time	14.3 months	17.8 months	16.1 months	15.1 months
ORR	91.3 %	67.9%	81%	84.6%
CR	10%	3.8%	0	3.3%
PR	63.8%	50.0%	81%	59.3%
PR-L	17.5%	14.2%	7%	22.0%

Safety Profile

Adverse events of special interest	orelabrutinib N=266 (%)	ibrutinib N= 1,124 (%)	acalabrutinib N= 612 (%)	zanubrutinib N= 671(%)
Grade 3 or Grade 4 Atrial fibrillation	0.0%	4.0%	1.0%	0.6%
Diarrhea	7.1% (1 case for G3)	39.0%	38.4%	18.2%
Secondary malignancy	0.4% (1 case)	10.0%	10.6%	7.9%
≥ Grade 3 Infection	15.4%	24.0%	18.0%	21.3%

MCL (N=106, median follow time of 15 months)

- 87 (87.9%) patients achieved ORR and 93.9% patients achieved disease control.
- CR rate, by conventional CT method, increased to 27.4% and it was expected a higher rate of in depth response may occur with prolonged treatment.
- The median PFS and OS were not reached

Sources: Imbruvica Prescribing Information, Jan 2019

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hanatologic Malignancies, John C. Byrd, et al., Blood, 2017; 130:4326 NDABLA Multi-disciplinary Review and Evaluation, 210259Orig15000, Center for Drug Evaluation and Research Pooled Analysis of Safety Data from Monotherapy Studies of the Bruton Tyrosine Kilmase (BTK) Inhibitor, Zanubrutinib (BGB-3111), in B-Cell Malignancies, S. Tam C., et al., European Hematology Association, Jun 15, 2019; 266776, PS1159

Presented by Wei Xu at ASH 2020. Xu W, et al. J Hematol Oncol . 2020 May 11;13(1):48.

Huang X, et al. Cancer Med. 2018 Apr;7(4):1043-55.

Byrd JC, et al. 2017 ASCO poster 272.


Ghia P, et al. J Clin Oncol . 2020 May 27; JCO1903355

"Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients with Chronic Lymphocytic or Mantle Cell Lymphoma" by Susan O'Brien, et al., Original Study, 2018; 18(10), 648-657. e15


Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor for Autoimmune Diseases



Initiated a randomized, double-blind, placebo-controlled and multi-center phase II Study in Relapsing-Remitting multiple sclerosis patients (RRMS), which will be conducted in the US and several European countries. The trial is expected to enroll 160 patients.



Robust Pre-clinical Efficacy Profile



MS Competitive Landscape: BTKi at Clinical Stage

Generic Name/ Drug Code	Company	MOA	Global Filing Status
Orelabrutinib	NNOCARE	Irreversible covalent	Phase II
SAR442168	Sanofi / Principia	Irreversible covalent	Phase III
Evobrutinib	Merck KGaA	Irreversible covalent	Phase III
Fenebrutinib	Roche	Reversible non-covalent	Phase III


Source: Frost & Sullivan Analysis

Potential to Become Best-in-Class

- Orelabrutinib demonstrated good Brain Blood Barrier penetration in certain patients in lymphoma trials
- Better BTK target selectivity
- Better Target Occupancy
- · Superior safety profile observed so far


Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor for Autoimmune Diseases (Cont'd)


- · Prevalence of SLE and other major autoimmune diseases (RA, MS, Psoriasis and LN) expected to grow rapidly
- Robust Pre-clinical Efficacy Profile in both SLE and RA
- Initiated a Phase Ib/IIa trial in combination with standard of care treatment for SLE in China, and completed first patient enrollment



Abbreviations: LN = lupus nephritis, MS = multiple sclerosis, RA = rheumatoid arthritis

Rapidly Growing SLE Therapeutic Market Size





SLE Competitive Landscape: Orelabrutinib vs. Other BTKi at Clinical Stage

Generic Name/Drug Code	Company	Global Filing Status
Orelabrutinib	INNOCARE	Phase I (China)
Fenebrutinib	Roche	Phase II
Evobrutinib	Merck KGaA	Phase II
ABBV-105	AbbVie	Phase II
BIIB068	Biogen	Phase I
AC0058	ACEA Pharma	Phase I
SN1011	SinoMab	Phase I


1 NO BTKi approved for the treatment of SLE in the global market

Huge unmet medical needs

INNOCARE


诺诚健华







Favorable Pre-clinical Profile with Improved Target Selectivity and High FGFR Inhibition Potency




CP-192: Potential Best-in-class Pan-FGFR Inhibitor (cont'd)



Patient enrollment ongoing in Phase II clinical trials

Clinical program



Ð


One of the most advanced pan-FGFR inhibitors under clinical development in China

	Patients with FGF/FGFR alterations
Total patients, n	30
Evaluable patients, n	12
CR, n	1 (8.3%)
PR, n	3 (25%)
SD, n	7 (53.8%)
DCR, %	91.7

ICP-723: Second Generation pan-TRK Inhibitor



- In the phase I dose escalation, two cohorts (1 and 2 mg) were completed and no treatment related SAE or DLT were observed
- PK data showed that the plasma exposure was high, which is within the range of efficacious exposure in preclinical models, and T1/2 is around 18 hours, supporting the once-daily dosing.



1. NTRK fusion-positive cancers and TRK inhibitor therapy Emiliano Cocco, Maurizio Scaltritiand Alexander Drilon

CP-105: Potential First-in-class FGFR4 Inhibitor



Plan to initiate a


pathway

overactivation


Phase II trial in HCC patients with FGFR4

Observed good correlation between exposure and PD biomarker (C4 and FGF19) changes during dose escalation study

Robust Pre-clinical Profile



ICP-105's Clinical Program



Key Pre-clinical Drug Candidates



	●ICP-332 ●	● ICP-033 ●	● ICP-189●
Asset Overview	 A small-molecule inhibitor of TYK2, a non-receptor tyrosine kinase that mediates immune signaling. ICP-332 was designed to be a potent and selective TYK2 inhibitor with 400 fold selectivity against JAK2 to avoid the adverse events associated with non selective JAK inhibitors 	 A multi-kinase inhibitor mainly targeting DDR1 and VEGFR that inhibits angiogenesis and tumor cell invasion, normalizes abnormal blood vessels, and reverses the immunosuppressive state of the tumor microenvironment 	 An oral allosteric inhibitor of SHP2 with excellent selectivity over other phosphatases. A non-receptor protein tyrosine phosphatase involved in mediating RAS signaling pathway and immune checkpoint pathway for regulation of cellular proliferation and survival
Indication	 T-cell mediated autoimmune diseases, disorders, such as psoriasis, IBD and SLE 	 In combination with immunotherapy and other targeted therapy drugs for liver cancer, renal cell carcinoma, colorectal cancer and other solid tumors 	 Solid tumors as a single agent and/or in combinations with other antitumor agents
Planned IND Application	 Submitted and accepted in March 2021 	 First half of 2021 	 Second half of 2021

Key Pre-clinical Drug Candidates (cont'd)



	ICP-488	ICP-490	ICP-248	ICP-B03
Asset Overview	 A small molecule binder JH2 of TYK2. JH2 has an important regulatory role in TYK2 kinase catalytical activity, and mutations in JH2 have been shown cause of, or be linked with impaired TYK2 activity. ICP-488 is a potent and selective TYK2 allosteric inhibitor that, by binding the TYK2 JH2 domain, blocks IL- 23, IL- 12, type 1 IFN and other inflammatory cytokine receptors 	 An orally small molecule inhibitor that modulates the immune system and other biological targets. By specifically binding to CRL4^{CRBN}-E3 ligase complex, it induces ubiquitination and degradation of transcription factors including Ikaros and Aiolos Relapsed/refractory 	 A novel, orally bioavailable B-cell lymphoma-2 (BCL-2) selective inhibitor. By increasing metabolic stability and reducing impact on liver drug enzymes, ICP-248 to be more suitable for combinational therapies. We are confident that the combination of ICP-248 and Orelabrutinib will overcome resistance seen in existing BCL-2 inhibitors Combination of ICP-248 	 A tumor-conditional pro- interleukin (IL) – 15 targeting and changing immune cells inside tumor microenvironment. IL-15 is a cytokine that stimulates important anti-tumor immune cells, such as CD8+ T cells and Natural Killer (NK) cells Improve anti-tumor
Indication Planned	 Inflammatory diseases such as psoriasis and IBD 	multiple myeloma, diffuse large B cell lymphoma (DLBCL) and autoimmune diseases	and Orelabrutinib for the treatment of ALL, AML, FL, CLL, DLBCL and other hematological malignancies	efficacies of existing therapies, such as immune checkpoint inhibitors, chemotherapies etc.
IND Application	Second half of 2021	First half of 2022	 First half of 2022 	 Second half of 2022



Appendix

Other Information



	Year ended December 31, 2020	
RMB'000	2019	2020
Revenue	1,247	1,364
Gross Profit	1,247	1,364
2 Other Income and Gains	104,449	271,304
Selling and Distribution Expenses	(3,458)	(68,208)
Research and Development Costs	(213,123)	(402,771)
Administrative Expenses	(63,623)	(89,371)
Other Expenses	(159,909)	(33,863)
Fair Value Changes of Convertible Redeemable Preferred Shares	(1,814,018)	(141,579)
Finance Costs	(1,916)	(1,139)
Share of Profits and Losses of Joint Ventures	-	-
Loss Before Tax	(2,150,351)	(464,263)
Loss for the Year	(2,150,351)	(464,263)
Loss for the Year / Period Excluding Fair Value Changes	(336,333)	(322,684)

Revenue was mainly generated from providing research and development services to biopharmaceutical companies; no product sales have been generated to date. Our sources of revenue are expected to become more diversified as Orelabrutinib launched into the market.

Other Income and Gains

2

primarily attributable to (i) RMB108.0 million increase in exchange gain due to the IPO offshore RMB exchanging to US\$; (ii) RMB24.8 million increase in bank interest income from RMB72.0 million in 2019 to RMB96.8 million in 2020; and (iii) RMB36.1 million increase in government grants from PRC local government authorities to support our subsidiaries' research and development activities from RMB28.3 million in 2019 to RMB64.4 million in 2020.

Fair Value Changes of Convertible Redeemable Preferred Shares represents fair value increase of preferred shares issued by us from prior financing rounds



	As at 31 De	ecember
RMB'000	FY2019	FY2020
Non-Current Assets		
Property, Plant and Equipment	48,479	306,398
Goodwill	3,125	3,125
Other Intangible Assets	37,011	37,017
Right-of-use Assets	86,311	96,733
Investments in Joint Ventures	1,159	1,159
Other Non-current Assets	30,861	1,045
Total Non-current Assets	206,946	445,477
Current Assets		
Inventories		1,878
Trade Receivables	37	152
Deposits, Prepayments and Other Receivables	36,590	120,563
Investments Measured at Fair Value through Profit or Loss	80,347	_

3,969,640

2,291,773

2,408,747 4,092,233

Cash and Bank Balances
Total Current Assets

Balance Sheet (Cont'd)



	As at 31 December	
RMB'000	FY2019	FY2020
Current Liabilities		
Trade Payables	8,197	5,520
Other Payables and Accruals	41,528	85,454
Deferred Income	645	6,646
Lease Liabilities	6,204	6,833
Loans from a Related Party	9,098	-
Total Current Liabilities	65,672	104,453
Net Current (Liabilities) / Assets	2,343,075	3,987,780
Total Assets Less Current Liabilities	2,550,021	4,433,257
Non-current Liabilities		
Convertible Redeemable Preferred Shares	4,213,772	-
Convertible Loan	1,117,176	1,149,550
Lease Liabilities	3,394	17,165
Deferred Income	157,389	100,000
Deferred Tax Liabilities	6,036	6,036
Total Non-current Liabilities	5,497,767	1,272,751
Equity		
Share Capital	4	16
Reserves	(3,004,714)	3,103,996
Non-controlling Interests	56,964	56,494
Total Equity	(2,947,746)	3,160,506

Convertible Redeemable Preferred Shares Represents fair value of preferred shares issued by us from prior financing rounds